NASDAQ:PTIProteostasis Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Proteostasis Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.11 -0.05 (-4.31 %) (As of 04/8/2020 08:00 AM ET) Add Compare Share Today's Range$1.10Now: $1.11▼$1.1950-Day Range$0.89MA: $1.40▼$2.0052-Week Range$0.61Now: $1.11▼$4.72Volume562,800 shsAverage Volume1.54 million shsMarket Capitalization$57.88 millionP/E RatioN/ADividend YieldN/ABeta0.99 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study. It has a collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingProteostasis Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.33, Proteostasis Therapeutics has a potential upside of 380.5% from its current price of $1.11.Amount of Analyst CoverageProteostasis Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesProteostasis Therapeutics has received 307 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProteostasis Therapeutics has received 436 “underperform” votes. (Add your “underperform” vote.)Community SentimentProteostasis Therapeutics has received 58.68% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote “Outperform” if you believe PTI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProteostasis Therapeutics does not currently pay a dividend.Dividend GrowthProteostasis Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Proteostasis Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 19.80% of the stock of Proteostasis Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 21.73% of the stock of Proteostasis Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Proteostasis Therapeutics are expected to grow by 4.81% in the coming year, from ($1.04) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Proteostasis Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Proteostasis Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProteostasis Therapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.37 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTI Previous Symbol CUSIPN/A CIK1445283 Webhttp://www.proteostasis.com/ Phone617-225-0096Debt Debt-to-Equity Ratio0.19 Current Ratio6.88 Quick Ratio6.88Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5 million Price / Sales11.58 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book0.91Profitability EPS (Most Recent Fiscal Year)($1.16) Net Income$-59,130,000.00 Net MarginsN/A Return on Equity-74.97% Return on Assets-57.97%Miscellaneous Employees48 Outstanding Shares52,148,000Market Cap$57.88 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive PTI News and Ratings via Email Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PTI Rates by TradingView Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions How has Proteostasis Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PTI shares have decreased by 4.3% and is now trading at $1.11. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Proteostasis Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Proteostasis Therapeutics. When is Proteostasis Therapeutics' next earnings date? Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Proteostasis Therapeutics. How were Proteostasis Therapeutics' earnings last quarter? Proteostasis Therapeutics Inc (NASDAQ:PTI) announced its quarterly earnings results on Tuesday, March, 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.06. View Proteostasis Therapeutics' earnings history. What price target have analysts set for PTI? 4 analysts have issued 12-month price targets for Proteostasis Therapeutics' stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Proteostasis Therapeutics' stock price to reach $5.33 in the next twelve months. This suggests a possible upside of 380.5% from the stock's current price. View analysts' price targets for Proteostasis Therapeutics. Has Proteostasis Therapeutics been receiving favorable news coverage? Headlines about PTI stock have trended very negative recently, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Proteostasis Therapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutProteostasis Therapeutics. Are investors shorting Proteostasis Therapeutics? Proteostasis Therapeutics saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 3,749,000 shares, a decline of 17.2% from the February 27th total of 4,530,000 shares. Based on an average trading volume of 962,700 shares, the short-interest ratio is presently 3.9 days. Approximately 11.0% of the shares of the stock are sold short. View Proteostasis Therapeutics' Current Options Chain. Who are some of Proteostasis Therapeutics' key competitors? Some companies that are related to Proteostasis Therapeutics include Minerva Neurosciences (NERV), ProQR Therapeutics (PRQR), Seres Therapeutics (MCRB), Fulcrum Therapeutics (FULC), AMAG Pharmaceuticals (AMAG), Geron (GERN), Arcturus Therapeutics (ARCT), Aduro BioTech (ADRO), XOMA (XOMA), MannKind (MNKD), Abeona Therapeutics (ABEO), Lexicon Pharmaceuticals (LXRX), Recro Pharma (REPH), Protagonist Therapeutics (PTGX) and Uluru (ULUR). What other stocks do shareholders of Proteostasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Micron Technology (MU), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Rite Aid (RAD), Clearside Biomedical (CLSD), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Syndax Pharmaceuticals (SNDX) and Clovis Oncology (CLVS). Who are Proteostasis Therapeutics' key executives? Proteostasis Therapeutics' management team includes the following people: Ms. Meenu Chhabra, Pres, CEO & Director (Age 47)Dr. Benito Munoz, Chief Scientific Officer (Age 57)Dr. Po-Shun Lee, Exec. VP & Chief Medical Officer (Age 50)Ms. Sandra Zimmerman, VP of Fin., Principal Financial Officer & Principal Accounting OfficerMs. Sheila Gilbride Wilson, Chief Operating Officer When did Proteostasis Therapeutics IPO? (PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers. What is Proteostasis Therapeutics' stock symbol? Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI." How do I buy shares of Proteostasis Therapeutics? Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Proteostasis Therapeutics' stock price today? One share of PTI stock can currently be purchased for approximately $1.11. How big of a company is Proteostasis Therapeutics? Proteostasis Therapeutics has a market capitalization of $57.88 million and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 48 workers across the globe. View additional information about Proteostasis Therapeutics. What is Proteostasis Therapeutics' official website? The official website for Proteostasis Therapeutics is http://www.proteostasis.com/. How can I contact Proteostasis Therapeutics? Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: What is total return in investing?
